Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Barter

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|December 17, 2013
International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemiaPhilip Barter
International Journal of Clinical Practice. Supplement|December 3, 2003
Introduction. Lipids, inflammation and CVD--understanding the basics to break the atherosclerosis cyclePhilip Barter
The American Journal of Cardiology|November 10, 2009
Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialPhilip Barter
Atherosclerosis|February 17, 2019
HDL cholesterol and ASCVD risk stratification: A debatePhilip Barter, Jacques Genest
Atherosclerosis. Supplements|April 27, 2002
Lipid-lowering--translating evidence into benefitsJames Shepherd, Philip Barter
Journal of Atherosclerosis and Thrombosis|August 19, 2014
Antioxidant effects of statins in the management of cardiometabolic disordersSoo Lim, Philip Barter
Nature Clinical Practice. Cardiovascular Medicine|May 27, 2006
Are we lowering LDL cholesterol sufficiently?Philip Barter, Kerry-Anne Rye
Trends in Pharmacological Sciences|November 18, 2011
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?Philip Barter, Kerry-Anne Rye
The American Journal of Cardiology|October 22, 2008
Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemiaPhilip Barter, Henry N Ginsberg
Plos One|May 23, 2012
Phenotypic and functional changes in blood monocytes following adherence to endotheliumColin Tso, Kerry-Anne Rye, Philip Barter
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|December 17, 2013
International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemiaPhilip Barter
International Journal of Clinical Practice. Supplement|December 3, 2003
Introduction. Lipids, inflammation and CVD--understanding the basics to break the atherosclerosis cyclePhilip Barter
The American Journal of Cardiology|November 10, 2009
Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialPhilip Barter
Atherosclerosis|February 17, 2019
HDL cholesterol and ASCVD risk stratification: A debatePhilip Barter, Jacques Genest
Atherosclerosis. Supplements|April 27, 2002
Lipid-lowering--translating evidence into benefitsJames Shepherd, Philip Barter
Journal of Atherosclerosis and Thrombosis|August 19, 2014
Antioxidant effects of statins in the management of cardiometabolic disordersSoo Lim, Philip Barter
Nature Clinical Practice. Cardiovascular Medicine|May 27, 2006
Are we lowering LDL cholesterol sufficiently?Philip Barter, Kerry-Anne Rye
Trends in Pharmacological Sciences|November 18, 2011
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?Philip Barter, Kerry-Anne Rye
The American Journal of Cardiology|October 22, 2008
Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemiaPhilip Barter, Henry N Ginsberg
Plos One|May 23, 2012
Phenotypic and functional changes in blood monocytes following adherence to endotheliumColin Tso, Kerry-Anne Rye, Philip Barter
Pageof 8